A short history of the B-cell-associated surface molecule CD40

Frontiers in Immunology

Volumn 5, Issue SEP, 2014, Pages

  Clark, Edward A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Activation; B cell; CD40; Monoclonal antibody; Therapy

Indexed keywords

B LYMPHOCYTE DIFFERENTIATION FACTOR; CD18 ANTIGEN; CD20 ANTIGEN; CD40 ANTIGEN; CD72 ANTIGEN; DIFFERENTIATION ANTIGEN; HISTOCOMPATIBILITY ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; VIRUS ENVELOPE PROTEIN;

ANTIGENIC VARIATION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; GERMINAL CENTER; HLA TYPING; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84918532748     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00472     Document Type: Article

References (53)

1. Boyse EA, Old LJ. Some aspects of some normal and abnormal cell surface genetics. Annu Rev Genet (1969) 3:269-90. doi:10.1146/annurev.ge.03.120169.001413
2. Boyse EA, Old LJ, Scheid M. Selective gene action in the specification of cell surface structure. Am J Pathol (1971) 65:439-50.
3. Clark EA, Ledbetter JA. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A (1986) 83:4494-8. doi:10.1073/pnas.83.12.4494
4. Yokochi T, Holly RD, Clark EA. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol (1982) 128:823-7.
5. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A (1990) 87:5031-5. doi:10.1073/pnas.87.13.5031
6. Clark EA, Yokochi T. Human B cell and B cell blast-associated surface molecules defined with monoclonal antibodies. In: Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF, editors. Leucocyte Typing: Monoclonal Antibodies. Berlin: Springer Verlag (1984). p. 339-46.
7. Muraguchi A, Butler JL, Kehrl JH, Fauci AS. Differential sensitivity of human B cell subsets to activation signals delivered by anti-mu antibody and proliferative signals delivered by a monoclonal B cell growth factor. J Exp Med (1983) 157:530-46. doi:10.1084/jem.157.2.5308.
8. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med (1983) 157:583-90. doi:10.1084/jem.157.2.583
9. Robb R, Munck A, Smith KA. T cell growth factor receptors: quantitation, specificity and biological relevance. J Exp Med (1981) 154:1455-74. doi:10.1084/jem.154.5.1455
10. Yakura H, Shen FW, Kaemmer M, Boyse EA. Lyb-2 system of mouse B cells. Evidence for a role in the generation of antibody-forming cells. J Exp Med (1981) 153:129-35. doi:10.1084/jem.153.1.129
11. Subbarao B, Mosier DE. Induction of B lymphocyte proliferation by monoclonal anti-Lyb 2 antibody. J Immunol (1983) 130:2033-7.
12. Clark EA, Shu G, Ledbetter JA. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci USA (1985) 82:1766-70. doi:10.1073/pnas.82.6.1766
13. Corbel C, Melchers F. The synergism of accessory cells and of soluble alpha-factors derived from them in the activation of B cells to proliferation. Immunol Rev (1984) 78:51-74. doi:10.1111/j.1600-065X.1984.tb00476.x
14. Golay JT, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol (1985) 135:3795-801.
15. O'Keefe EJ, Pledger WJ. A model of cell cycle control: sequential events regulated by growth factors. Mol Cell Endocrinol (1983) 31:167-86. doi:10.1016/0303-7207(83)90147-8
16. Stiles CD. The biological role of oncogenes -insights from platelet-derived growth factor: Rhoads memorial award lecture. Cancer Res (1985) 45:5215-8.
17. Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J (1989) 8:1403-10.
18. Torres RM, Clark EA. Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation. J Immunol (1992) 148:620-6.
19. Bishop GA. The multifaceted roles of TRAFs in the regulation of B-cell function. Nat Rev Immunol (2004) 4:775-86. doi:10.1038/nri1462
20. Clark EA, Shu G. Association between IL-6 and CD40 signaling. IL-6 induces phosphorylation of CD40 receptors. J Immunol (1990) 145:1400-6.
21. Jabara HH, Fu SM, Geha RS, Vercelli D. CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med (1990) 172:1861-4. doi:10.1084/jem.172.6.1861
22. Barrett TB, Shu G, Clark EA. CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J Immunol (1991) 146:1722-9.
23. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigen-driven selection in germinal centres. Nature (1989) 342:929-31. doi:10.1038/342929a0
24. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, et al. Molecular and biological characterization of a murine ligand for CD40. Nature (1992) 357:80-2. doi:10.1038/357080a0
25. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A (1992) 89:6550-4. doi:10.1073/pnas.89.14.6550
26. Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol (1992) 149:3817-26.
27. Bonelli M, Shih HY, Hirahara K, Singelton K, Laurence A, Poholek A, et al. Helper T cell plasticity: impact of extrinsic and intrinsic signals on transcriptomes and epigenomes. Curr Top Microbiol Immunol (2014) 381:279-326. doi:10.1007/82_2014_371
28. Perez-Shibayama C, Gil-Cruz C, Ludewig B. Plasticity and complexity of B cell responses against persisting pathogens. Immunol Lett (2014) S0165-2478(14):143-6. doi:10.1016/j.imlet.2014.07.003
29. Inui S, Kaisho T, Kikutani H, Stamenkovic I, Seed B, Clark EA, et al. Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40. Eur J Immunol (1990) 20:1747-53. doi:10.1002/eji.1830200819
30. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol (2000) 67:2-17.
31. Paulie S, Rosén A, Ehlin-Henriksson B, Braesch-Andersen S, Jakobson E, Koho H, et al. The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction. J Immunol (1989) 142:590-5.
32. Ling NR, Maclennan ICM, Mason DY. B-cell and plasma cell antigens: new and previously designed clusters. In: McMichael AJ, editor. Leucocyte Typing III: White Cell Differentiation Antigens. Oxford: Oxford University Press (1987). p. 302-35.
33. Hart DN, McKenzie JL. Isolation and characterization of human tonsil dendritic cells. J Exp Med (1988) 168:157-70. doi:10.1084/jem.168.1.157
34. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med (1993) 177:925-35. doi:10.1084/jem.177.4.925
35. Pinchuk LM, Polacino PS, Agy MB, Klaus SJ, Clark EA. The role of CD40 and CD80 accessory cell molecules in dendritic cell-dependent HIV-1 infection. Immunity (1994) 1:317-25. doi:10.1016/1074-7613(94)90083-3
36. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med (1994) 179:1109-18. doi:10.1084/jem.179.4.1109
37. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med (1994) 180:1263-72. doi:10.1084/jem.180.4.1263
38. Lanzavecchia A. Immunology. Licence to kill. Nature (1998) 393:413-4. doi:10.1038/30845
39. Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature (1994) 367:425-8. doi:10.1038/367425a0
40. Otipoby KL, Nagai Y, Shu GL, Miyake K, Clark EA. CD180 (RP105/Bgp95) workshop report. In: Mason DY, editor. Leukocyte Typing VII. White Cell Differentiation Antigens. Oxford: Oxford University Press (2002). p. 120-3.
41. Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M. RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J Immunol (1995) 154:3333-40.
42. Chaplin JW, Chappell CP, Clark EA. Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation, and immunological memory. J Exp Med (2013) 210:2135-46. doi:10.1084/jem.20130188
43. Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv Exp Med Biol (2009) 647:8-36. doi:10.1007/978-0-387-89520-8_2
44. Esposito P, Grosjean F, Rampino T, Libetta C, Gregorini M, Fasoli G, et al. Costimulatory pathways in kidney transplantation: pathogenetic role, clinical significance and new therapeutic opportunities. Int Rev Immunol (2014) 33:212-33. doi:10.3109/08830185.2013.829470
45. Xie JH, Yamniuk AP, Borowski V, Kuhn R, Susulic V, Rex-Rabe S, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J Immunol (2014) 192:4083-92. doi:10.4049/jimmunol.1303239
46. Hassan SB, Sørensen JF, Olsen BN, Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol (2014) 36:96-104. doi:10.3109/08923973.2014.890626
47. Benoit NE, Wade WF. Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin. Immunopharmacology (1996) 35:129-39. doi:10.1016/S0162-3109(96)00138-5
48. Lewis TS, McCormick RS, Emmerton K, Lau JT, Yu SF, McEarchern JA, et al. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin Cancer Res (2011) 17:4672-81. doi:10.1158/1078-0432.CCR-11-0479
49. Jak M, van Bochove GG, Reits EA, Kallemeijn WW, Tromp JM, Umana P, et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood (2011) 118:5178-88. doi:10.1182/blood-2011-01-331702
50. von Scheidt B, Leung PS, Yong MC, Zhang Y, Towne JE, Smyth MJ, et al. Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. Cancer Res (2014) 74:2412-21. doi:10.1158/0008-5472.CAN-13-1646
51. Fransen MF, Cordfunke RA, Sluijter M, van Steenbergen MJ, Drijfhout JW, Ossendorp F, et al. Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. Vaccine (2014) 32:1654-60. doi:10.1016/j.vaccine.2014.01.056
52. Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, et al. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res (2014) 2:80-90. doi:10.1158/2326-6066.CIR-13-0067
53. Wallemacq H, Bedoret D, Pujol J, Desmet C, Drion PV, Farnir F, et al. CD40 triggering induces strong cytotoxic T lymphocyte responses to heat-killed Staphylococcus aureus immunization in mice: a new vaccine strategy for Staphylococcal mastitis. Vaccine (2012) 30:2116-24. doi:10.1016/j.vaccine.2012.01.039